12/23
07:27 am
aplt
Applied Therapeutics, Inc. (NASDAQ: APLT) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
Low
Report
Applied Therapeutics, Inc. (NASDAQ: APLT) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
12/23
07:27 am
aplt
Applied Therapeutics, Inc. (NASDAQ: APLT) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
Low
Report
Applied Therapeutics, Inc. (NASDAQ: APLT) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
12/23
06:59 am
aplt
Rating for APLT
Low
Report
Rating for APLT
12/23
06:59 am
aplt
Rating for APLT
Low
Report
Rating for APLT
12/23
05:36 am
aplt
Applied Therapeutics downgraded to Market Perform from Outperform at William Blair
Low
Report
Applied Therapeutics downgraded to Market Perform from Outperform at William Blair
12/23
05:36 am
aplt
Applied Therapeutics downgraded to Market Perform from Outperform at William Blair
Low
Report
Applied Therapeutics downgraded to Market Perform from Outperform at William Blair
12/20
09:13 am
aplt
Rating for APLT
Medium
Report
Rating for APLT
12/20
09:13 am
aplt
Rating for APLT
Medium
Report
Rating for APLT
12/3
07:53 am
aplt
Applied Therapeutics, Inc. (NASDAQ: APLT) was upgraded by analysts at William Blair to a "strong-buy" rating.
Low
Report
Applied Therapeutics, Inc. (NASDAQ: APLT) was upgraded by analysts at William Blair to a "strong-buy" rating.
12/3
07:53 am
aplt
Applied Therapeutics, Inc. (NASDAQ: APLT) was upgraded by analysts at William Blair to a "strong-buy" rating.
Low
Report
Applied Therapeutics, Inc. (NASDAQ: APLT) was upgraded by analysts at William Blair to a "strong-buy" rating.
12/2
08:06 am
aplt
Applied Therapeutics, Inc. (NASDAQ: APLT) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $2.00 price target on the stock, down previously from $13.00.
High
Report
Applied Therapeutics, Inc. (NASDAQ: APLT) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $2.00 price target on the stock, down previously from $13.00.
12/2
07:29 am
aplt
Rating for APLT
High
Report
Rating for APLT
11/29
04:42 pm
aplt
Rating for APLT
High
Report
Rating for APLT
11/29
04:42 pm
aplt
Rating for APLT
High
Report
Rating for APLT